Pharma Pioneer

Verismo Submits FDA Application for IND Approval of SynKIR™-310 for Treating Recurrent or Refractory B-cell NHL

17 May 2024
2 min read

Verismo Therapeutics, a company specializing in CAR T-cell therapies, is progressing with its second clinical trial using the SynKIR™ platform. The trial focuses on patients suffering from various subtypes of B-cell Non-Hodgkin Lymphoma (B-cell NHL), including Diffuse Large B Cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL), who have either relapsed after CAR T-cell therapy or are unresponsive to it. The IND application for SynKIR™-310 has been submitted to the FDA for this Phase 1 clinical study.
Despite the high initial response rates of approved CAR T-cell therapies, relapses occur in about 40-50% of patients, largely due to the therapies' inability to maintain long-term T cell function and presence. Verismo aims to address this issue with SynKIR™-310, which utilizes a proprietary CD19 binder, DS191, developed to target B-cell disorders and potentially extend the lifespan of anti-tumor T cells.
Dr. Laura Johnson, Verismo's Chief Scientific Officer, expressed optimism about SynKIR™-310's potential to enhance T cell persistence and prevent early relapse in aggressive lymphomas. The clinical trial, named CELESTIAL-301, is set to commence in 2024, following regulatory approval.
The KIR-CAR platform, which SynKIR™-310 is based on, is a multi-chain CAR T-cell therapy that has demonstrated the ability to sustain anti-tumor activity in challenging conditions. This novel approach combines NK cell-derived KIR and DAP12 signaling, offering a distinct activation and co-stimulation mechanism. The platform is being explored in conjunction with other emerging technologies to develop advanced, targeted immunotherapies for patients.
Verismo's flagship product, SynKIR™-110, is already in Phase 1 clinical trials (STAR-101) and is expected to expand to additional sites in the second quarter of 2024. The company is a frontrunner in KIR-CAR technology, focusing on improving treatment outcomes for aggressive tumors and B-cell related conditions, which are areas with significant unmet medical needs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Preliminary Phase 1/2 Clinical Trial Results for mRNA-3927, a Potential mRNA Treatment for Propionic Acidemia, Featured in Nature Journal
Pharma Pioneer
2 min read
Preliminary Phase 1/2 Clinical Trial Results for mRNA-3927, a Potential mRNA Treatment for Propionic Acidemia, Featured in Nature Journal
17 May 2024
Moderna, a biotechnology company, has reported preliminary results from a phase 1/2 clinical trial for mRNA-3927.
Read →
Achilles Therapeutics Reports Interim Phase I/IIa Results for Clonal Neoantigen T Cells in NSCLC and Melanoma with Enhanced Conditioning
Pharma Pioneer
3 min read
Achilles Therapeutics Reports Interim Phase I/IIa Results for Clonal Neoantigen T Cells in NSCLC and Melanoma with Enhanced Conditioning
17 May 2024
Achilles Therapeutics plc has reported interim Phase I/IIa clinical trial data for clonal neoantigen reactive T cells (cNeT) from the CHIRON study for non-small cell lung cancer (NSCLC) and the THETIS study for malignant melanoma
Read →
CureVac Reveals Positive Interim Phase 2 Results for Seasonal Flu Vaccine in Partnership with GSK
Pharma Pioneer
3 min read
CureVac Reveals Positive Interim Phase 2 Results for Seasonal Flu Vaccine in Partnership with GSK
17 May 2024
This innovative vaccine, developed by CureVac, is multivalent and contains antigens that match the four flu strains recommended by the World Health Organization (WHO).
Read →
Eilean Therapeutics Granted Approval to Launch Phase I R/R AML Clinical Trial Utilizing Lomonitinib, a Targeted FLT3/IRAK4 Inhibitor
Pharma Pioneer
2 min read
Eilean Therapeutics Granted Approval to Launch Phase I R/R AML Clinical Trial Utilizing Lomonitinib, a Targeted FLT3/IRAK4 Inhibitor
17 May 2024
Eilean Therapeutics LLC has received approval from the Human Research Ethics Committee in Australia to commence a Phase I clinical trial for lomonitinib (ZE46-0134).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.